Welcome to our dedicated page for Tempus AI news (Ticker: TEM), a resource for investors and traders seeking the latest updates and insights on Tempus AI stock.
Tempus AI Inc (NASDAQ: TEM) pioneers AI-driven healthcare solutions through its proprietary data integration platform. This news hub provides investors and healthcare professionals with essential updates on the company's technological advancements, strategic partnerships, and financial developments.
Access real-time announcements covering TEM's innovations in diagnostic analytics, generative AI applications, and healthcare data ecosystem expansions. Our curated collection includes earnings reports, regulatory filings, and analyses of platform enhancements that power precision medicine.
Key focus areas include AI-powered laboratory solutions, clinical research collaborations, and progress in breaking healthcare data silos. Stay informed about TEM's role in advancing personalized diagnostics through machine learning and large language model implementations.
Bookmark this page for verified updates on TEM's operational milestones, directly sourced from official communications. Monitor how the company continues redefining medical data utilization while maintaining HIPAA-compliant security standards across its platform.
Tempus AI (NASDAQ: TEM) announced the acceptance of 18 abstracts for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago. The presentations include one oral and multiple poster sessions showcasing the company's AI-driven research in oncology.
Key research highlights include: 1) An oral presentation examining SF3B1 hotspot mutations in breast cancer, analyzing data from 420 patients; 2) A poster on NUTM1 structural variants, identifying 59 NUT carcinoma patients with an 81% NUTM1 fusion rate; 3) A study of 109 patients evaluating circulating tumor DNA as a biomarker for tyrosine kinase inhibitor therapy response; and 4) A collaborator-led presentation with T-knife Therapeutics on TCR-T therapy targeting PRAME-positive solid tumors.
Tempus AI (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, has scheduled its first quarter 2025 financial results announcement for Tuesday, May 6, 2025. The earnings conference call will be held at 4:30 p.m. ET on the same day.
The presentation will feature CEO Eric Lefkofsky and CFO Jim Rogers. Investors can access the live audio webcast through Tempus' Investor Relations website's events page or join via phone using the conference ID 4680302 (Domestic: 800-715-9871, International: 646-307-1963).
Tempus AI (NASDAQ: TEM) has announced multi-year strategic collaborations with AstraZeneca and Pathos AI to develop the largest multimodal foundation model in oncology. The partnerships will focus on:
- Gathering biological and clinical insights
- Discovering novel drug targets
- Developing therapeutics for the oncology community
The agreements include $200 million in data licensing and model development fees to Tempus. The collaboration expands on Tempus' existing 2021 partnership with AstraZeneca, utilizing Tempus' AI-enabled platform and multimodal data repository to advance therapeutic programs in oncology globally. The foundation model will be built using Tempus' de-identified oncology data and will be shared among all three parties to enhance their respective patient care initiatives.
Tempus AI (NASDAQ: TEM) has announced the formation of its Advisory Board, comprising distinguished physicians from leading medical institutions across the United States. The board will provide strategic guidance on research, product development, and clinical utility of Tempus's AI-enabled platform for precision medicine.
Led by Dr. Ezra Cohen, Chief Medical Officer of Oncology at Tempus, the advisory board includes 13 renowned medical professionals specializing in various oncology fields. Notable members include directors and professors from prestigious institutions such as Ohio State University Medical Center, UCLA, MD Anderson Cancer Center, Mayo Clinic, and Vanderbilt-Ingram Cancer Center.
The advisory board's primary focus will be maintaining high standards and ensuring the company's strategy remains grounded in expert knowledge, supporting Tempus's mission of advancing precision medicine and patient care through AI technology.
Illumina (NASDAQ: ILMN) and Tempus AI (NASDAQ: TEM) have announced a strategic collaboration to accelerate the clinical adoption of next-generation sequencing tests through AI-driven innovation. The partnership aims to combine Illumina's AI technologies with Tempus's multimodal data platform to enhance genomic algorithms and expand molecular profiling across various disease categories.
The collaboration focuses on developing evidence to standardize comprehensive genomic profiling and molecular testing beyond cancer, extending to cardiology, neurology, and immunology. This builds upon the companies' existing partnership in developing tools and assays for testing needs from preemptive screening through therapy selection.
The initiative addresses the current gap where patients often miss precision medicine benefits due to non-standardized molecular profiling across disease areas and regions. The partnership will leverage data analytics and sequencing technologies to improve patient outcomes and advance precision medicine research.
Tempus AI (NASDAQ: TEM) reported strong financial results for Q4 and full-year 2024. Q4 revenue grew 35.8% year-over-year to $200.7M, with Genomics revenue at $120.4M (30.6% growth) and Data and services at $80.2M (44.6% growth). Q4 gross profit increased 49.7% to $122.1M.
Full-year 2024 revenue reached $693.4M, up 30.4% YoY, with Genomics contributing $451.7M and Data services $241.6M. The company achieved 140% net revenue retention and ended with $940M in Total Remaining Contract Value. The net loss for 2024 was ($705.8M), including $547.7M in stock compensation expenses.
Following the Ambry Genetics acquisition in February 2025, Tempus increased its 2025 revenue guidance to $1.24B, projecting 79% annual growth. The company expects Adjusted EBITDA of $5M for 2025, marking a $110M improvement over 2024.
Tempus AI (NASDAQ: TEM) announced its first-time presentation of 4 research abstracts at the American College of Cardiology (ACC) Annual Meeting from March 29-31 in Chicago. The abstracts showcase the company's AI applications in cardiovascular care.
The research includes: (1) Machine learning models for predicting left ventricular systolic dysfunction, (2) EHR-integrated notifications for sudden cardiac arrest risk assessment, (3) Study on racial disparities in valvular heart disease from April 2019 to January 2024, and (4) Natural language processing application in cardiac transthyretin amyloidosis diagnosis.
According to Dr. Brandon Fornwalt, SVP of Cardiology at Tempus, the company aims to enable clinicians to provide improved, guideline-recommended care for patients with undiagnosed or undertreated cardiovascular disease through their AI-enabled insights and provider network.
Tempus AI (NASDAQ: TEM), a technology company focused on advancing precision medicine and patient care through artificial intelligence, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The conference is scheduled for April 7-10, 2025.
The company's Chief Financial Officer, Jim Rogers, will engage in a fireside discussion on Wednesday, April 9. The event will be accessible to viewers through a live webcast.
Tempus AI (NASDAQ: TEM) has announced the acquisition of Deep 6 AI, a leading AI-powered precision research platform. Deep 6 AI's network spans over 750 provider site locations and more than 30 million patients, which will significantly expand Tempus' existing infrastructure.
Deep 6 AI specializes in clinical trial optimization, patient recruitment acceleration, and real-world evidence generation. Their AI software matches patients to clinical trials by analyzing real-time structured and unstructured EMR data across various healthcare institutions, including academic medical centers, NCI-Designated Cancer Centers, and NCI Community Oncology Research Programs.
The acquisition aims to enhance Tempus' connectivity efforts and strengthen its ability to deploy critical applications like Next (for closing care gaps) and TIME (for matching patients to clinical trials).
Tempus AI (NASDAQ: TEM) reported strong Q4 2024 results with revenue increasing 35.8% year-over-year to $200.7 million. The company's Genomics segment generated $120.4 million (+30.6% YoY), while Data and services reached $80.2 million (+44.6% YoY).
Q4 gross profit grew 49.7% to $122.1 million, with net loss improving to ($13.0 million) from ($50.5 million) in Q4 2023. For full year 2024, revenue increased 30.4% to $693.4 million, with Genomics contributing $451.7 million and Data services $241.6 million.
The company completed the Ambry Genetics acquisition on February 3, 2025, and received FDA approval for xT CDx diagnostic device with a $4,500 reimbursement rate. Tempus projects 2025 revenue of $1.24 billion (+79% growth) and expects positive Adjusted EBITDA of $5 million, marking a $110 million improvement over 2024.
